Clinical trial · Observational
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiation segmentectomy (RS) refers to selective infusion of Y-90 microspheres to the tumor bearing hepatic segment of hepatic artery. Majority of the data on RS is based on the Glass microspheres experience. Due to different properties of Resin and Glass microspheres description of dose limits to the segment for effectiveness of treatments with Resin microspheres are needed. Based on this background in this study it is aimed to evaluate the safety and efficacy of RS with resin microspheres in HCC patients. Secondly, it is planned to describe the dose limits for complete radiological response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer, Adult | Malignant Liver Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Radiation Segmentectomy Group
- description
- Patients who will receive radioembolization for radiation segmentectomy intent
Primary outcomes (1)
- measure
- Effectiveness of radiation segmentectomy
- timeFrame
- 3 months after treatment
- description
- Evaluation of response with modified RECIST criteria
Secondary outcomes (1)
- measure
- Safety of radioembolization in radiation segmentectomy intent
- timeFrame
- 3 months after treatment
- description
- Evaluation of toxicity of radiation segmentectomy at the 3 month of treatment with CTCAE grading
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥18 years * Underwent RE as a RS intent (have single or \<3 tumors in same or neighboring 2 segments) for the treatment of HCC or metastatic tumor to liver. * Presence of extrahepatic disease * Tumor size less than 8 cm * Child Pugh Score \<B9 Exclusion Criteria: * Presence of macrovascular invasion, * Presence of extrahepatic disease, * Cholangiocarcinoma or mixed HCC-cholangiocarcinoma * Not willing to attend follow-up visits.
References
Publications (0)
Data not yet available